Validation of an HPLC-CAD method for measuring the lipid content of novel LNP-encapsulated COVID-19 mRNA vaccines.

Validation of an HPLC-CAD method for measuring the lipid content of novel LNP-encapsulated COVID-19 mRNA vaccines.

Publication date: Dec 01, 2024

Lipid nanoparticles (LNPs) are frequently employed as mRNA vaccine delivery vehicles. LNPs are made up of four types of lipids: cationic lipid, PEG-lipid conjugate, zwitterionic helper phospholipid, and cholesterol. LNP distribution efficiency is significantly impacted by lipid composition, which also controls LNP stability and bilayer fluidity. The various lipids used in the formulation system have distinct properties and contents. To aid in the development of new drugs and vaccines, we developed and validated an HPLC-CAD method for identifying and determining the amounts of four lipids in Yuxi Watson Biotechnology Co. , Ltd. ‘s LNP-encapsulated COVID-19 mRNA vaccines (OmicronXBB. 1.5).

Concepts Keywords
Biotechnology COVID-19
Cholesterol COVID-19
Nanoparticles COVID-19 Vaccines
Vaccine COVID-19 Vaccines
Humans
Lipid Nanoparticles
Lipid nanoparticles (LNPs)
Lipids
Lipids
Liposomes
Liposomes
Method validation
mRNA Vaccines
mRNA Vaccines
MRNA vaccines
Nanoparticles
SARS-CoV-2
Vaccines, Synthetic
Vaccines, Synthetic

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Cholesterol

Original Article

(Visited 2 times, 1 visits today)